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We studied recent antibiograms (2010 to 2011) from 12 hospitals in the Hampton Roads area, Virginia, that refer
patients to a tertiary-care facility affiliated with Eastern Virginia Medical School. The data was compiled into a
regional antibiogram, and sensitivity rates of common isolates from the tertiary-care facility (central) were compared
to those of referring hospitals grouped by locale. Staphylococcus aureus was the most common Gram- positive and
E. coli the most common Gram- negative organism grown from clinical samples in the area. Overall 53% of S.aureus
isolates were resistant to oxacillin. There was a broad scatter of MIC (minimum inhibitory concentration) for vancomycin
within the susceptibility range, and MIC of 4 μg/mL was reported in 2012. Penicillin resistance was seen in 50% and
erythromycin resistance in 45% of Streptococcus pneumoniae. Vancomycin resistance was seen in 75% of Enterococcus
faecium and 2% of Enterococcus faecalis respectively. Acinetobacter baumannii was the most resistant Gram negative
organism in the data compiled. Among the Escherichia coli, 26%, 44% and 52%were resistant to Trimethoprim/
Sulfamethoxazole ( SXT) ampicillin- sulbactam and ampicillin respectively. We found significant differences in
methodology, interpretation and antibiotic panels used by area laboratories. Based on these findings, we are now
prospectively following resistance patterns in the tertiary-care facility, sharing data, and creating a consistent
approach to antimicrobial susceptibility testing in the region.
Keywords: Antibacterial susceptibility, Antibiogram, Antibiotic resistance, Antibiotic utilization, Antimicrobial
stewardship, Antimicrobial susceptibility, SurveillanceBackground
National databases are unlikely to prove useful in making
antimicrobial use in communities more appropriate. Such
databases of academic and educational value are useful
for microbiologists and infectious disease clinicians. In the
community, however, databases are less useful because: 1)
most antimicrobial drug prescriptions in the community
are written by primary care physicians who generally do
not use these resources, 2) industry-generated data are
often used to highlight a particular antimicrobial agent, 3)
there are regional differences in antimicrobial resistance
patterns, which, at times, may not reflect clearly in national
databases, and 4) a significant number of patients are
transferred from local hospitals in the region to tertiary-
care/referral hospitals. The appropriate management of
serious, non-resolving infections in the transferred patients
should be guided by resistance patterns prevalent in the* Correspondence: khardoNM@evms.edu
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unless otherwise stated.referring hospital. Because of prior antimicrobial therapy,
the repeat cultures done at the receiving hospital often do
not yield helpful results.
To date, regional studies concerning antimicrobial resist-
ance patterns in the Hampton Roads area of Virginia, a
region with a diverse and a high population density have
been limited [1]. More common are studies that concen-
trate on one particular organism or group of organisms
and its resistance patterns in the United States by regions
encompassing larger areas, such as “East North Central”
and Mid-Atlantic regions or entire states in the United
States [2-4]. These studies had the benefit of the Surveil-
lance and Control of Pathogens of Epidemiological Im-
portance (SCOPE)—MediMedia Information Technology
(MMIT) Antimicrobial Monitoring Network. This net-
work surveyed nosocomial infections across the United
States and is based at Virginia Commonwealth University
in Richmond, Virginia [5]. The database provided access
to a vast amount of data that also was linked to specific
subjects, but it since ended its activities in 2004 [5]. Asides is an Open Access article distributed under the terms of the Creative
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Prevention (CDC) publish its own reports that trace anti-
biotic susceptibilities across the United States [6]. However,
this is national data, which is useful for comparisons and
for surveillance but not so much for treatment guidance at
the regional and local levels. The aim of this retrospective
study was to compile the region-wide antibiotic resistance
data and categorize it by central (tertiary care) and the
referring hospitals by locale. The availability of a regional
antibiogram allows for dissemination and sharing of pre-
vailing resistance patterns And selection of more appropri-
ate antimicrobial therapy at the referring as well as tertiary
care hospitals.
Methods
Requests for the two most-recent antibiograms were
sent to microbiology laboratories of the sixteen hospitals
that refer patients to a tertiary-care center in the region
of southeastern Virginia known as Hampton Roads. The
latest available antibiograms were for the years 2010 and
2011. Seventy-five percent of the referring hospitals
responded. These hospitals reflected the variety of locales
served in the area, for not only does the tertiary-care facil-
ity receive patients from Hampton Roads, but also trans-
fers from hospitals in western Virginia and northern North
Carolina. In essence, patients from seventeen hospitals
within a seventy-mile radius converge are sent to this one
“central” hospital.
Data from a total of twelve responding hospitals along
with data from the central hospital (n = 13) were com-
bined into a regional antibiogram. The region was di-
vided arbitrarily into four geographical areas with the
tertiary-care facility at the central point. The northwest
region included 3 hospitals, northeast 4, southwest 4,
and southeast 1 hospital. The antibiotics presented in
this paper are ones tested at the central hospital since
the testing panels used were different for various hospi-
tals. The referring hospitals may test more or less antibi-
otics on particular isolates. This manuscript is based
on a summary of diverse experimental procedures used
by the microbiology laboratories from the participating
hospitals. The P values were derived by unpaired T-tests
using an online calculator.
Results and discussion
Overall, Staphylococcus aureus (19,515 isolates) was the
most common organism isolated, followed closely by
Escherichia coli (18,812). Coagulase-negative staphylo-
cocci, Klebsiella pneumoniae, Pseudomonas aeruginosa,
and Enterobacter species were among the next five most
frequently reported organisms (Tables 1 and 2).
Oxacillin resistance was demonstrated in 53% of S.
aureus with the range in different areas being 51% to
58% (susceptibility of 42% to 49%, P < 0.0001).This wasin comparison to oxacillin resistance rates of 44% to
58% reported by National Health Care safety Network
(NHSN) for 2009 -2010. All tested isolates were suscep-
tible to vancomycin, daptomycin, and linezolid. Because
of differences in methodology and interpretation, we
were able to determine vancomycin intermediate resist-
ance only at limited locations. There was a broad scatter
of MIC with vancomycin that was within the susceptibil-
ity range, and MIC of 4 μg/mL was reported in the year
2012. Additionally with S. aureus, susceptibility range
was 97% to 99% for trimethoprim-sulfamethoxazole
(SXT), 94% to 97% for tetracycline (P < 0.0001), and 69%
to 79% for clindamycin (P < 0.0001).
Only 39% of coagulase-negative staphylococci were
susceptible to oxacillin. Among Enterococcus faecalis, 97%
were susceptible to ampicillin and 98% to vancomycin.
Ampicillin and vancomycin susceptibility of Enterococcus
faecium were 10% and 25%, respectively compared to 625
to 93% resistance to Vancomycin reported by NHSN. Sus-
ceptibility of Streptococcus pneumoniae in the region varied
between 12% and 66% for penicillin and 41% and 65% for
erythromycin.
For E. coli, meropenem was the most active beta-lactam
(susceptibility 99% to 100%) and amikacin was the most
active aminoglycoside overall (99% to 100%). Overall, 29%
and 30% of E.coli were resistant to moxifloxacin and cipro-
floxacin respectively. NHSN (2009-2010 ) reported 25% to
42% E.coli to be resistant to quinolones. The difference in
the susceptibility of E. coli to ampicillin and to ampicillin/
sulbactam was statistically significant at 48% and 56%,
respectively (P < 0.0001).
Meropenem and amikacin were the most effective
agents against K. pneumoniae, Enterobacter aerogenes,
and Enterobacter cloacae.
Acinetobacter baumannii data differed widely across
the regions. Susceptibility to amikacin ranged from 50%
(126 isolates) to 84% (211) with 67% (505) for all reporting
hospitals. The susceptibilty range for gentamicin was 8%
(37) to 70% (233) with 51% (1,045) for all reporting hospi-
tals. And for ampicillin/sulbactam, the susceptibility range
was 66% (144) to 78% (37) with 75% (870) overall.
The increased prevalence of antibiotic resistant strains
is associated with greater morbidity, mortality, and
healthcare cost [7]. Thus, it is advantageous to have a
sense of resistance patterns in a region in order to decide
on the best antibiotic for use, lessening the drain on time
and resources from increased lengths of stay, multiple trials
of antibiotics, and/or non-judicious use of broad-spectrum
antibiotics [8]. Unfortunately, the trend is towards in-
creased use of broad-spectrum antimicrobials, because of
their relative ease of use [9]. However, the threat of devel-
oping resistance to what is seen as the current last line of
defense against disease-causing microbes is very real, as
seen with the rare but documented vancomycin-resistant
Table 1 Susceptibility results of common Gram-positive bacteria to select antimicrobial agents
% isolates susceptible (no. isolates reported)
Organism/region
(no. isolates tested)
AMP CFZ CTX CLI DAP ERY GEN LZD MXF NIT OXA PEN Q-D TET SXT VAN
Staphylococcus
aureus
All (19,515) - 46 (18,727) - 72 (19,253) 100 (7,041) - 98 (12,956) 100 (11,037) - - 47 (18,727) - - 96 (19,315) 99 (19,312) 100 (18,890)
Central (3,602) - 49 (3,602) - 72 (3,402) 100 (1,712) - 99 (1,712) 100 (1,712) - - 49 (3,602) - - 96 (3,402) 99 (3,402) 100 (3,402)
Northwest (3,883) - 45 (3,883) - 70 (3,883) 100 (1,531) - 98 (3,883) 100 (2,710) - - 44 (3,883) - - 94 (3,883) 98 (3,883) 100 (3,883)
Northeast (5,389) - 48 (5,045) - 67 (5,327) 100 (2,995) - 97 (5,045) 100 (4,725) - - 48 (5,045) - - 97 (5,389) 99 (5,386) 100 (5,389)
Southwest (6,246) - 45 (5,802) - 79 (6,246) 100 (576) - 98 (1,921) 100 (1,495) - - 46 (5,802) - - 96 (6,246) 98 (6,246) 100 (5,821)
Southeast (395) - 42 (395) - 69 (395) 100 (227) - 98 (395) 100 (395) - - 42 (395) - - 94 (395) 97 (395) 100 (395)
Coagulase-negative
staphylococci
All (13,289) - 38 (12,784) - 64 (13,160) - - 85 (9,644) - - - 39 (12,143) - - 83 (11,833) - 100 (13,237)
Central (3,043) - 33 (3,043) - 58 (3,043) - - 82 (1,332) - - - 33 (3,043) - - 82 (3,043) - 100 (3,043)
Northwest (2,420) - 41 (2,420) - 62 (2,420) - - 85 (2,420) - - - 42 (2,038) - - 83 (2,420) - 100 (2,420)
Northeast (4,764) - 42 (4,475) - 66 (4,635) - - 86 (4,476) - - - 42 (4,379) - - 83 (4,764) - 100 (4,764)
Southwest (2,548) - 35 (2,332) - 69 (2,548) - - 83 (902) - - - 38 (2,169) - - 84 (1,092) - 100 (2,496)
Southeast (514) - 45 (514) - 72 (514) - - 89 (514) - - - 45 (514) - - 81 (514) - 100 (514)
Streptococcus
pneumoniae
All (2,294) - - 91 (706) - - 55 (972) - - 99 (803) - - 50 (2,294) - 75 (813) - 100 (956)
Central (195) - - 87 (186) - - 54 (186) - - 97 (102) - - 52 (195) - 79 (186) - 100 (186)
Northwest (430) - - 92 (169) - - 57 (190) - - 100 (169) - - 31 (430) - 74 (190) - 100 (216)
Northeast (429) - - 96 (278) - - 64 (314) - - 100 (278) - - 50 (429) - 75 (314) - 100 (230)
Southwest (1,044) - - 88 (41) - - 41 (250) - - 97 (222) - - 66 (1,044) - 71 (91) - 100 (292)
Southeast (196) - - 81 (32) - - 65 (32) - - 100 (32) - - 12 (196) - 82 (32) - 100 (32)
Organism/region
(no. isolates tested)
AMP CFZ CTX CLI DAP ERY GEN LZD MXF NIT OXA PEN Q-D TET SXT VAN
Enterococcus faecalis
All (4,390) 97 (4,254) - - - - - - 99 (2,914) - 97 (3,966) - 97 (4,174) - - - 98 (4,390)
Central (777) 98 (777) - - - - - - 100 (413) - 99 (413) - 98 (777) - - - 98 (777)
Northwest (1,200) 97 (1,200) - - - - - - 100 (604) - 99 (1,200) - 97 (1,200) - - - 98 (1,200)
Northeast (1,391) 98 (1,255) - - - - - - 99 (1,100) - 99 (1,331) - 98 (1,255) - - - 98 (1,391)

















Table 1 Susceptibility results of common Gram-positive bacteria to select antimicrobial agents (Continued)
Southeast (148) 98 (148) - - - - - - 98 (148) - 99 (148) - 98 (148) - - - 100 (148)
Enterococcus
faecium
All (1,090) 10 (1,072) - - - - - - 98 (951) - - - 10 (1,057) 99 (951) - - 25 (1,089)
Central (248) 8 (248) - - - - - - 100 (109) - - - 8 (248) 100 (109) - - 22 (248)
Northwest (257) 9 (257) - - - - - - 97 (257) - - - 9 (257) 99 (257) - - 30 (257)
Northeast (441) 11 (363) - - - - - - 98 (441) - - - 10 (424) 98 (441) - - 23 (441)
Southwest (105) 13 (31) - - - - - - 96 (105) - - - 11 (89) 99 (105) - - 25 (104)
Southeast (39) 18 (39) - - - - - - 97 (39) - - - 18 (39) 100 (39) - - 33 (39)
Abbreviations: AMP ampicillin, CFZ cefazolin, CTX cefotaxime, CLI clindamycin, DAP daptomycin, ERY erythromycin, GEN gentamicin, LZD linezolid, MXF moxifloxacin, NIT nitrofurantoin, OXA oxacillin, PEN penicillin, Q-D

















Table 2 Susceptibility results of common Gram-negative bacteria to select antimicrobial agents
% isolates susceptible (no. isolates reported)
Organism/region
(no. isolates tested)
AMK AMP SAM AZM CFZ FEP CFT CIP GEN MEM MXF NIT TZP TGC TOB SXT
Escherichia coli
All (18,812) 99 (18,475) 48 (18,475) 56 (18,475) 93 (11,881) 87 (14,583) 95 (18,475) 94 (18,524) 70 (17,614) 88 (18,475) 100 (13,780) 71 (8,138) 90 (17,749) 94 (17,277) 99 (14,500) 90 (17,277) 74 (18,812)
Central (2,195) 100 (2,195) 47 (2,195) 58 (2,195) 93 (2,195) 85 (2,195) 94 (2,195) 92 (2,195) 65 (2,195) 89 (2,195) 100 (2,195) 69 (2,195) 93 (2,195) 93 (2,195) 100 (2,195) 90 (2,195) 73 (2,195)
Northwest (3,291) 100 (3,291) 47 (3,291) 58 (3,291) 95 (3,291) 88 (2,851) 95 (3,291) 94 (3,291) 69 (2,690) 87 (3,291) 100 (2,851) 72 (2,082) 88 (3,291) 91 (2,690) 98 (2,082) 90 (2,690) 77 (3,291)
Northeast (4,919) 99 (4,919) 49 (4,919) 58 (4,919) 93 (4,919) 85 (4,919) 94 (4,919) 92 (4,919) 64 (4,653) 90 (4,919) 100 (4,296) 63 (3,096) 85 (4,770) 93 (4,653) 100 (2,970) 88 (4,653) 72 (4,919)
Southwest (8,824) 99 (8,487) 49 (8,487) 54 (8,487) 93 (1,893) 88 (4,595) 97 (8,487) 96 (8,536) 76 (8,493) 87 (8,487) 99 (4,785) 95 (1,182) 93 (7,910) 96 (8,156) 99 (7,670) 90 (8,156) 75 (8,824)
Southeast (496) 99 (496) 51 (496) 62 (496) 93 (496) 96 (496) 89 (496) 95 (496) 89 (496) 74 (496) 100 (126) 95 (496) 79 (126) 90 (126) 95 (496) 98 (496) 93 (496)
Pseudomonas
aeruginosa
All (5,317) 94 (5,317) - - 63 (3,719) - 80 (5,129) - 71 (4,666) 78 (5,317) 86 (4,709) - - 86 (4,704) - 94 (4,704) -
Central (951) 96 (951) - - 63 (951) - 80 (951) - 76 (951) 81 (951) 86 (951) - - 86 (951) - 96 (951) -
Northwest (757) 97 (757) - - 67 (757) - 84 (649) - 65 (507) 78 (757) 89 (649) - - 83 (507) - 90 (507) -
Northeast (1,483) 94 (1,483) - - 62 (1,483) - 78 (1,483) - 64 (1,387) 76 (1,483) 84 (1,427) - - 83 (1,387) - 92 (1,387) -
Southwest (2,106) 93 (2,106) - - 63 (508) - 80 (2,004) - 77 (1,779) 77 (2,106) 88 (1,640) - - 91 (1,817) - 95 (1,817) -
Southeast (142) 96 (142) - - 64 (142) - 84 (56) - 75 (56) 77 (142) 89 (56) - - 83 (56) - 95 (56) -
Proteus mirabilis
All (4,566) 100 (4,511) 83 (4,511) 90 (4,511) 89 (3,357) 86 (3,734) 90 (4,511) 91 (4,537) 69 (4,189) 93 (4,511) 100 (3,980) 64 (2,315) - 97 (3,878) - 96 (3,878) 76 (4,566)
Central (641) 100 (641) 88 (641) 89 (641) 88 (641) 84 (641) 85 (641) 85 (641) 65 (641) 98 (641) 100 (641) 65 (641) - 97 (641) - 98 (641) 74 (641)
Northwest (725) 100 (725) 84 (725) 90 (725) 93 (725) 91 (644) 91 (725) 91 (725) 70 (580) 91 (725) 100 (725) 73 (448) - 99 (499) - 95 (499) 75 (725)
Northeast (1,442) 100 (1,442) 72 (1,442) 89 (1,442) 85 (1,442) 80 (1,442) 83 (1,442) 85 (1,442) 56 (1,358) 95 (1,442) 100 (1,236) 50 (999) - 95 (1,358) - 97 (1,358) 67 (1,442)
Southwest (1,840) 99 (1,785) 88 (1,785) 91 (1,785) 94 (631) 93 (1,086) 98 (1,785) 97 (1,811) 80 (1,692) 91 (1,785) 100 (1,538) 97 (309) - 99 (1,459) - 95 (1,459) 84 (1,840)
Southeast (107) 100 (107) 72 (107) 86 (107) 76 (107) 80 (29) 74 (107) 75 (107) 66 (107) 66 (107) 100 (29) 90 (107) - 100 (29) - 100 (29) 92 (107)
Organism/region
(no. isolates tested)
AMK AMP SAM AZM CFZ FEP CFT CIP GEN MEM MXF NIT TZP TGC TOB SXT
Klebsiella
pneumoniae
All (6,848) 93 (6,806) - 79 (6,806) 84 (5,087) 84 (5,895) 88 (6,806) 88 (6,840) 87 (6,435) 94 (6,806) 93 (5,627) 79 (3,957) - 89 (6,259) 94 (5,530) 89 (6,393) 85 (6,848)
Central (1,422) 90 (1,275) - 75 (1,275) 87 (1,275) 81 (1,275) 89 (1,275) 88 (1,275) 85 (1,275) 96 (1,275) 94 (1,275) 86 (1,275) - 89 (1,275) 96 (1,275) 87 (1,275) 84 (1,275)
Northwest (1,101) 97 (1,101) - 84 (1,101) 91 (1,101) 88 (906) 91 (1,101) 91 (1,101) 90 (946) 97 (1,101) 98 (906) 91 (839) - 93 (751) 96 (839) 93 (946) 90 (1,101)
Northeast (1,687) 89 (2,204) - 75 (2,204) 81 (2,204) 78 (2,204) 83 (2,204) 81 (2,204) 80 (2,094) 89 (2,204) 88 (2,052) 71 (1,666) - 86 (2,094) 92 (1,618) 81 (2,094) 81 (2,204)
Southwest (2,414) 97 (2,372) - 84 (2,372) 84 (653) 91 (1,595) 94 (2,372) 94 (2,406) 94 (2,266) 96 (2,372) 96 (1,479) 80 (323) - 91 (2,224) 95 (1,944) 97 (2,224) 89 (2,414)

















Table 2 Susceptibility results of common Gram-negative bacteria to select antimicrobial agents (Continued)
Serratia marcescens
All (991) 99 (954) - - 97 (632) - 99 (917) 97 (954) 93 (971) 97 (954) 99 (863) - - 91 (917) 96 (920) 93 (954) 98 (971)
Central (319) 99 (319) - - 98 (319) - 99 (319) 97 (319) 91 (319) 99 (319) 100 (319) - - 93 (319) 96 (319) 98 (319) 99 (319)
Northwest (65) 100 (65) - - 99 (65) - 100 (65) 99 (65) 92 (65) 100 (65) 100 (65) - - 100 (65) 100 (65) 99 (65) 95 (65)
Northeast (231) 100 (231) - - 96 (231) - 99 (231) 96 (231) 93 (231) 97 (231) 99 (227) - - 94 (231) 96 (197) 93 (231) 99 (231)
Southwest (376) 100 (359) - - 89 (37) - 98 (322) 97 (359) 95 (376) 96 (359) 99 (272) - - 86 (322) 95 (359) 87 (359) 96 (376)
Southeast (0) - - - - - - - - - - - - - - - -
Enterobacter
aerogenes
All (824) 100 (790) - - 83 (493) - 99 (763) 83 (493) 93 (802) 99 (790) 99 (657) - - 81 (763) 97 (749) 99 (790) 96 (802)
Central (216) 100 (216) - - 84 (216) - 99 (216) 84 (216) 95 (216) 99 (216) 99 (216) - - 76 (216) 96 (216) 99 (216) 97 (216)
Northwest (69) 100 (69) - - 82 (69) - 100 (69) 79 (69) 94 (69) 100 (69) 100 (69) - - 73 (69) 96 (69) 100 (69) 97 (69)
Northeast (203) 100 (203) - - 82 (203) - 100 (203) 82 (203) 88 (203) 98 (203) 99 (186) - - 78 (203) 99 (162) 98 (203) 93 (203)
Southwest (336) 100 (324) - - 85 (27) - 99 (297) 100 (27) 96 (336) 99 (324) 100 (208) - - 89 (297) 97 (324) 99 (324) 97 (336)
Southeast (0) - - - - - - - - - - - - - - - -
Organism/region
(no. isolates tested)
AMK AMP SAM AZM CFZ FEP CFT CIP GEN MEM MXF NIT TZP TGC TOB SXT
Enterobacter
cloacae
All (1,795) 100 (1,773) - - 78 (1,293) - 96 (1,711) 77 (1,295) 86 (1,692) 95 (1,773) 99 (1,551) 86 (988) - 76 (1,608) 93 (1,462) 95 (1,670) 87 (1,795)
Central (388) 100 (388) - - 80 (388) - 98 (388) 80 (388) 93 (388) 98 (388) 100 (388) 95 (388) - 82 (388) 96 (388) 98 (388) 96 (388)
Northwest (350) 100 (350) - - 66 (350) - 95 (324) 64 (350) 62 (309) 89 (350) 99 (324) 66 (247) - 49 (283) 87 (247) 87 (309) 77 (350)
Northeast (456) 100 (456) - - 82 (456) - 98 (456) 81 (456) 89 (427) 96 (456) 100 (436) 89 (342) - 84 (427) 94 (316) 96 (427) 85 (456)
Southwest (627) 100 (605) - - 84 (125) - 94 (568) 91 (127) 92 (594) 95 (605) 99 (428) 100 (37) - 78 (535) 94 (537) 96 (572) 88 (627)
Southeast (65) 100 (25) - - 80 (25) - - 96 (25) 84 (25) 96 (25) - 96 (25) - - 80 (25) 88 (25) 100 (25)
Acinetobacter
baumannii
All (1,100) 67 (505) - 75 (870) - - 40 (823) - 40 (734) 51 (1,045) 50 (737) - - 39 (71) - 63 (884) 51 (1,058)
Central (222) 50 (126) - 77 (222) - - 35 (222) - 36 (222) 50 (222) 47 (222) - - - - 57 (222) 49 (222)
Northwest (144) 65 (72) - 66 (144) - - 45 (144) - 45 (108) 60 (144) 82 (108) - - 41 (36) - 88 (108) 55 (144)
Northeast (409) 56 (96) - 77 (409) - - 27 (246) - 20 (201) 42 (409) 39 (333) - - 11 (20) - 48 (364) 41 (409)
Southwest (279) 84 (211) - 66 (144) - - 57 (211) - 63 (203) 70 (233) 79 (37) - - 73 (15) - 82 (190) 68 (246)
Southeast (46) - - 78 (37) - - - - - 8 (37) 38 (37) - - - - - 48 (37)
Abbreviations: AMK amikacin, AMP ampicillin, SAM ampicillin/sulbactam, AZM aztreonam, CFZ cefazolin, FEP cefepime, CFT ceftriaxone, CIP ciprofloxacin, GEN gentamicin, IMI imipenem, MEM meropenem, MXF
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carbapenem-resistant Enterobacteriaceae (CRE) [10,11].
Therefore the prudent and judicious use of available agents
at this time is absolutely necessary [12]. Resistance can de-
velop and spread quickly as seen with carbapenem resist-
ance mediated by New Delhi metallo-β-lactamase, which
was documented in 2006 and then spread to five conti-
nents over a span of less than ten years [13]. There is
plenty of interest in antimicrobial stewardship but the
optimization of antimicrobial use has not been achieved
even with the availability of national data bases [14].
One of the limitations with national publications is
that they tend to focus on hospital-acquired pathogens,
which typically are resistant to more antibiotics compared
to community-acquired infections. Then again, data from
many hospital antibiograms, including the ones used in
our study, are a conglomerate of isolates from patients
coming from the community and of those already in a
healthcare setting, either at the central hospital or trans-
ferred from other facilities. This observation also compli-
cates how we survey regional trends. A majority of the
time, susceptibility data to measure regional trends comes
from hospital-associated laboratories. It is cost-effective
and easier to review data that has been compiled already,
and there is little practicality in collecting specimens from
the community for a battery of susceptibility testing when
the resources are limited. The use of hospital antibiograms,
however, likely overestimates resistance in the community.
Patients who are more ill tend to be ones treated in-facility
as opposed to patients with less-serious infections who re-
ceive prescriptions for antibiotics on an outpatient basis.
Patients with more resistant infections tend to have sam-
ples collected for culture [15]. And an often overlooked
factor is that hospitals may serve populations that are
different from the community surrounding it [16]. Even
with these challenges, CDC states that antibiograms can
be used to monitor regional trends and to alert us to in-
creasing resistance in an area [16].
There are a few studies that have focused on regional
resistance patterns. They demonstrated geographical var-
iations in antimicrobial susceptibilities, emphasizing the
utility of local surveillance as compared with national
data. Much fewer studies examined smaller, more defined
areas, which have their own resistance patterns as well. For
instance, the Delmarva region of the eastern United States
harbors more gentamicin-resistant Escherichia coli due to
the ubiquitous poultry industry compared to the remainder
of the Chesapeake Bay region [17]. Even hospitals have
their own trends with higher rates of resistance manifesting
in infections acquired in intensive care units compared
to nosocomial infections from other units in the same
hospital [18].
Our study is modeled after a previous study published
in 2005 in the central Illinois area that requested andcompiled antimicrobial resistance data from hospitals
that referred patients to a tertiary-care center [8]. We
examined resistance patterns in the region as generated
by in-house antibiograms and derived a regional antibio-
gram which was shared with all participating institu-
tions. Despite the limitations of hospital antibiograms,
this tailored antibiogram was more relevant to health-
care in the area compared to national data bases and
antibiograms for individual hospitals and to specific anti-
biograms for individual hospitals. National databases are
too broad for the regional variability in bacterial resist-
ance, and hospital-specific antibiograms are not broad
enough to encompass the network that is the healthcare
system. We also will discuss susceptibility patterns of
commonly-isolated organisms and attempted to examine
evidence of multidrug resistance, which is intermediate
sensitivity or resistance to at least one antimicrobial agent in
at least three specific classes according to the National
Healthcare Safety Network [6].
Variable patterns of sensitivities do exist within the
Hampton Roads region. This is not surprising with dif-
ferent patient populations, conditions, environments, and
antibiotic preferences within the area. However, dramatic
swings in sensitivities seen especially with A. baumannii
and E. cloacae may be due to the small number of isolates
tested as opposed to actual large differences by locales.
Because of the geography-based method we used to
group the hospitals, the Southeast region was composed
of one hospital. The small number of isolates from that
region predictably resulted in substantial swings in
susceptibility data.
As for multidrug resistance of regional isolates, inter-
pretation is limited due to the reasons aforementioned,
along with the current inability to identify intermediate
resistance, to distinguish duplicate samples, and to dif-
ferentiate between community-acquired and nosocomial
pathogens on a majority of the antibiograms from out-
side institutions. However, even with these challenges,
some discussion of the results is warranted. S. aureus at
one of the sites in our study had been vancomycin sensi-
tive until an MIC of 4 μg/mL was reported in 2012 (data
not shown). According to the Clinical and Laboratory
Standards Institute, this MIC puts these S. aureus isolates
in the intermediate-sensitivity range, which spans 4 to
8 μg/mL [19]. An MIC of ≥ 4 μg/mL is concerning enough
that CDC recommends retesting, and if confirmed, notifi-
cation of infection control, the health department, and
CDC. Unfortunately, the trend of decreased susceptibility
of S.aureus to vancomycin is not uncommon. Increasing
MICs can be seen in tertiary-care centers across the United
States [20,21].
The resistance pattern of S. pneumoniae deserves special
attention because of the magnitude of outpatient antibiotic
use for presumed bacterial respiratory tract infections. Link-
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microbial susceptibility of S. pneumoniae in theUnited States
[22]. The data from eight states during 2002 to 2006 and
2007 to 2009 were reported. Unfortunately, Virginia was not
one of the states included. The resistance rates to penicillin
ranged from 15% to 31% in first time frame and 12% to 29%
in the second. Our study inHampton Roads,Virginia, during
2010 to 2011 shows penicillin resistance in 34% to 88%
of isolates. Resistance to erythromycin during the same
time period was 35% to 59%. This information is being
used by the antibiotic stewardship team for two major
hospital groups in the area.
With E. coli, there is evidence of extended-spectrum
β-lactamase (ESBL) production as seen with reduced
susceptibility to third- and fourth-generation cephalospo-
rins, ceftriaxone and cefepime, respectively. ESBLs are not
uncommon nowadays, and E. coli that produce ESBL tend
to be resistant to a number of other antimicrobials such as
quinolones and sulfonamides, although resistance to these
antimicrobials is more common than resistance to the later
generation of cephalosporins [23]. The aminoglycoside
amikacin and the carbapenem meropenem showed high
activity against the E. coli isolates, staving off the fear of
significant carbapenem resistance lurking in the Hampton
Roads region for now. A. baumannii, an infamously diffi-
cult pathogen to manage, shows reduced susceptibility to
recommended agents, such as ampicillin/sulbactam, mero-
penem, amikacin, and tobramycin. Although some of the
isolates are resistant to these antimicrobials, they may be
susceptible to other agents in the same group, for example,
resistance to meropenem does not mean resistance to imi-
penem necessarily [24]. However, many of the hospitals
tested a small selection of agents and typically one agent
from each class. This highlights why careful and thorough
susceptibility testing is important for optimal treatment,
especially with an organism like A. baumannii.
There are several limitations with this study. Foremost
is the inherent inconsistency when requesting susceptibility
data from a number of different laboratories. Unlike the
studies done by Karlowsky and colleagues on the suscepti-
bility of specific organisms [2,25], which had the advantage
of having samples sent to one commercial laboratory, our
study was dependent on individual hospital microbiology
laboratories. Not only can testing methods differ secondary
to protocol and to staff training, but antibiograms can be
formulated variably, a phenomenon noted in a study by
Pakyz et al. [5]. In central Illinois, our group found that a
number of laboratories were not aware of the guidelines
concerning antibiogram analysis and presentation pub-
lished by the Clinical and Laboratory Standards Institute,
the M39-A guidelines [8]. A nationwide study by Zapantis
et al. found that as of 2002, 85% of the 209 institutions that
participated in their study were compliant with at least half
of ten M39-A guidelines [26]. The latest guideline is M39-A3, published in 2009 [27]. To date, there have been
no published studies that examine adherence. The hope
is that since then, compliance to the guidelines has im-
proved. However, it is difficult for institutions with limited
resources to do so, since it can take a significant amount of
manpower and of time to conduct a review of isolate origin,
laboratory practices, and data interpretation. Zapantis’ study
also found that 14% of the antibiograms reviewed showed
susceptibility results that should have alerted microbiology
personnel to further review [26]. Without microbiological
personnel oversight of the data generated by automated test-
ing methods, publishing an antibiogram simply would be
another task made to meet a nominal standard devoid of
clinical utility.
Another possible limitation with this study is isolate
anonymity since we used an already formulated data
base. The specimen source and patient profile were not
incorporated. Karlowsky’s studies had the advantage of
data connected to a sample, which included the patient’s
age, sex, and specimen source [2,25]. These nuances
may narrow organism susceptibility to specific situa-
tions, but it can be argued whether this additional infor-
mation may be too meticulous for the purposes of
creating an aggregate antibiogram for our region. Des-
pite these limitations, the data represent a current as-
sessment of the prevalence of antibiotic resistance in the
region in which patients are shared and transferred be-
tween health care facilities. To make the data less con-
fusing and more user friendly , it was divided into all ,
central ( tertiary care referral hospital ) and four sur-
rounding areas since we did not see any significant dif-
ferences in resistance patterns between facilities within
those four areas. The Tables 1 and 2 have been formu-
lated the same way as the facility antibiograms.
With the known serious shortcomings in susceptibility
testing due to variations in methodology, selection of
panels, interpretation, and reporting at the local regional
and national levela, we believe that cooperation and col-
laboration at the regional level may be the most useful
public health measure towards optimizing the role of
diagnostic microbiology in managing infections and anti-
microbial resistance. We are in the process of formaliz-
ing a regional advisory group with microbiology laboratory
personnel from all participating hospitals. This will allow
for greater ease of sharing data and standardization for
more appropriate comparisons. A master antibiogram
for the region will allow the tertiary care institution to
have information on resistance patterns in the referring
hospitals which will guide antibiotic changes upon trans-
fer. Updating the regional antibiogram once a year will
allow determination of changes in resistance patterns
and early recognition of “endemic resistance” based on
which interventions to reduce the impact on patient care
can be implemented.
Var et al. Annals of Clinical Microbiology and Antimicrobials  (2015) 14:22 Page 9 of 9Conclusions
The institutional antibiograms generated by the hospital
diagnostic laboratories are readily accessible and inexpen-
sive tool to monitor antimicrobial resistance patterns in
communities and regions. A regional antibiogram including
hospitals that transfer patients between them would allow
appropriate antimicrobial selection at transfer.
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